Our Infectious Disease program, K-NK-ID101, is initially focused on the development of K-NK cells as a treatment for COVID-19.
The unique properties of Kiadis K-NK cells make them ideally suited to fight SARS-CoV-2 and to be developed as pre-exposure prophylaxis and post-exposure pre-emptive therapy in high risk patients. K-NK cells enhance multiple aspects of antiviral immunity. In immunocompromised transplant patients, K-NK cells have shown significant reduction of potentially lethal CMV reactivation and BKV infection. K-NK cells work synergistically with antibodies, immunoglobulins and vaccines.
ABOUT K-NK Cells and COVID-19
COVID-19 breaks down NK cell immunity, and severe COVID-19 patients lack functional NK cells. K-NK-ID101 cells potentially have enhanced anti-viral activity, while avoiding exacerbating needless inflammation, and therefore may be uniquely suited to repair this lack of functional NK cells in people with severe COVID infection. Since K-NK-ID101 cells can be manufactured at large scale and frozen down, they can be immediately and globally made available to patients. Also, the broad anti-viral activity of K-NK cells could potentially serve as a universal countermeasure to fight future viral pandemics.
[Kiadis is supporting the development of the K-NK-ID101 program through government grants, and has received a $9.5 million grant through the Advanced Regenerative Manufacturing Institute, or ARMI, from the United States Department of Defense. Additionally, Kiadis has established a collaboration with ARMI to build state-of-the-art manufacturing capacity in the United States and accelerate the industrialization of K-NK-cell therapy. ARMI is funded by the United States Department of Defense to advance large-scale manufacturing of engineered tissues and tissue-related technologies, including cell therapy.]
Kiadis plans to initiate a phase 1/2 clinical trial evaluating use of K-NK cells to treat COVID 19 patients with government grant funding.